Prefest

Prefest is a brand name of estradiol/norgestimate, approved by the FDA in the following formulation(s):

PREFEST (estradiol; norgestimate - tablet; oral)

• 
  Manufacturer: TEVA WOMENS
  
  Approval date: October 22, 1999
  
  Strength(s): 1MG,1MG;N/A,0.09MG ^[RLD][AB]

Has a generic version of Prefest been approved?

A generic version of Prefest has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Prefest and have been approved by the FDA:

ESTRADIOL AND NORGESTIMATE (estradiol; norgestimate tablet; oral)

• 
  Manufacturer: BARR
  
  Approval date: April 29, 2005
  
  Strength(s): 1MG,1MG;N/A,0.09MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prefest. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Hormone preparation and method
  Patent 5,382,573
  Issued: January 17, 1995
  Inventor(s): Casper; Robert F.
  Assignee(s): Jencap Research Ltd.
  This invention is concerned with a contraceptive formulation and a method of contraception which employs a combination of estrogen and progestin and wherein a short period of relatively dominant estrogenic activity alternates with a short period of relatively dominant progestagenic activity. The invention also concerns a hormonal replacement formulation and method for use in menopausal or castrate women which employs a similar combination of estrogen and progestin.
  
  Patent expiration dates:
  
  
  • January 17, 2012
    
  
  



• 
  Low dose estrogen interrupted hormone replacement therapy
  Patent 6,747,019
  Issued: June 8, 2004
  Inventor(s): Robert F.; Casper & Gary A.; Shangold & Militza K.; Ausmanas
  Assignee(s): Jencap Research, Ltd.
  Ortho-McNeil Pharmaceutical, Inc.
  A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&bgr;-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&bgr;-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 &mgr;g per day of norgestimate.
  
  Patent expiration dates:
  
  
  • March 20, 2020
    
    ✓ 
    Patent use: HORMONE REPLACEMENT
  
  



• 
  Low dose estrogen interrupted hormone replacement therapy
  Patent 7,320,970
  Issued: January 22, 2008
  Inventor(s): Casper; Robert F. & Shangold; Gary A. & Ausmanas; Militza K.
  Assignee(s): Duramed Pharmaceutials, Inc.
  Jencap Research Ltd.
  A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 μg per day of norgestimate.
  
  Patent expiration dates:
  
  
  • March 30, 2020
    
    ✓ 
    Patent use: PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
    ✓ 
    Drug product
  
  

See also...

• Prefest Consumer Information (Wolters Kluwer)
• Prefest Consumer Information (Cerner Multum)
• Norgestimate with Ethinyl Estradiol Consumer Information (Wolters Kluwer)
• Estradiol and norgestimate Consumer Information (Cerner Multum)